Plasmonic nanobiosensors for detection of microRNA cancer biomarkers in clinical samples
Bridget M. Crawford(Duke University), Tuan Vo‐Dinh(Duke University), Dadong Zhang(Precision for Medicine (United States)), Katherine S. Garman(Duke University), Hsin‐Neng Wang(Duke University), Kouros Owzar(Duke University), Christina Stolarchuk(Duke University), Xiaodi Qin(Duke Cancer Institute), Richard J. von Furstenberg(Baylor College of Medicine), Pietro Strobbia(University of Cincinnati)
Cited by 35
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655